United States Patent 12,458,626: What Do the Claims Actually Cover?
US Drug Patent 12,458,626 is directed to oral palovarotene dosing regimens intended to reduce the volume of new heterotopic ossification (HO) in fibrodysplasia ossificans progressiva (FOP). The core claim architecture is built around:
- Phase-of-disease trigger: dosing changes based on whether the subject is experiencing at least one flare-up symptom versus not experiencing any flare-up symptom
- Fixed acute flare-up course: 28 days at a higher daily dose during symptomatic periods
- Fixed post-flare-down course: after the 28-day period, a lower daily dose for at least 56 days
- Weight and maturation stratification: multiple dependent claims and separate independent claims map to subject weight bands and/or skeletal maturity
- Optional extension logic: additional treatment for 28 more days if flare-up symptoms persist
The patent reads like a treatment schedule claiming a combination of indication + dosing + timing + patient stratification rather than claiming palovarotene itself or a broad method untethered from dosing.
What Is the Independent Claim Scope?
Claim 1
Claim 1 is the broadest “template” for dose escalation/de-escalation tied to flare-up status, with general subject characteristics.
Method: reduce volume of new HO in a subject with FOP comprising:
- (i) Non-flare period: during a period when the subject is not experiencing any flare-up symptom, palovarotene 5 mg orally daily
- (ii) Flare period: during a period when the subject is experiencing at least one flare-up symptom, palovarotene 20 mg orally daily for 28 days
- Post-flare: after 28 days, palovarotene 10 mg orally daily for at least 56 days
Key structural elements inside Claim 1
- Exact mg amounts: 5 mg → 20 mg (28 days) → 10 mg (≥56 days)
- Fixed timing: 28-day flare course and ≥56-day post-flare course
- Oral administration
- Trigger definition is functional: “flare-up symptom” occurs
Claims 7 and 13 and 17
The patent’s independent claims also include alternative dosing frameworks that are either:
- flare-start centric (Claim 7), or
- weight-band specific (Claims 13 and 17)
Claim 7
A method where the flare-up phase is explicit:
- during flare-up symptom: 20 mg daily for 28 days
- then 10 mg daily for at least 56 days
No explicit “non-flare” daily 5 mg maintenance is recited in Claim 7 (unlike Claim 1).
Claim 13 (weight band 10-20 kg)
A weight-tiered regimen:
- Non-flare (10–20 kg): 2.5 mg daily
- Flare: 10 mg daily for 28 days
- After 28 days: 5 mg daily for at least 56 days
Claim 17 (weight band 20-40 kg)
Another weight-tiered regimen:
- Non-flare (20–40 kg): 3 mg daily
- Flare: 12.5 mg daily for 28 days
- After 28 days: 6 mg daily for at least 56 days
Claim 21 (weight band 40-60 kg)
Weight-tiered again:
- Non-flare (40–60 kg): 4 mg daily
- Flare: 15 mg daily for 28 days
- After 28 days: 7.5 mg daily for at least 56 days
Where Does the Patent Create “Claim Barriers”? (Timing, Dose, and Trigger)
The claim barriers are the parts that are hardest to design around because they are both numerically specific and structurally linked:
1) Flare-up trigger definition is functional, not descriptive
Claims repeatedly require: the subject is experiencing at least one flare-up symptom, and “flare-up symptom” is narrowed in dependent claims to:
- swelling
- pain
- erythema
- warmth
- stiffness
- decreased range of motion
This creates a claim focus on clinical signs rather than, for example, imaging criteria. Dependent claims make this list explicit in:
- Claim 6, and
- Claims 12, 16, 20, 24 (each tied to the relevant independent claim family).
2) The flare course is fixed at 28 days
Across independent claims where flare dosing is defined, the flare dose is always for:
That fixed timepoint is a central hinge for claim infringement.
3) Post-flare duration is “at least 56 days,” with extension logic
Core structure:
- post-flare: ≥56 days at the intermediate daily dose
Dependent claims introduce extension:
- Claims 3, 9, 15, 19, 23 add an additional 28 days “if the subject continues to experience at least one flare-up symptom.”
This means the regimen is not only a dose schedule; it is also a response-adaptive duration tied to persistence of symptoms.
4) Weight/maturity gating can be a full or partial design-around
The patent includes:
- a “general” adult-style framework in Claim 1 (plus maturation/weight dependents),
- and separate weight-band independent claims (Claims 13, 17, 21).
If a competitor designed a regimen that avoided all claimed weight bands or used materially different weight cutoffs/dose levels, it might fall outside specific independent claims. But it could still be tested against the more general Claim 1 framework if the competitor’s patient selection still meets Claim 1 dependents (where present).
How Broad Are the Dependent Claims? (Patient Stratification and Symptom Lists)
Skeletal maturity and weight dependents
Claim 4: subject weighs > 60 kg
Claim 5: skeletal maturity 90% or greater
These are “gating” limitations attached to Claim 1 and likely intended to anchor dosing in a higher-maturity population.
Symptom list dependents
Claim 6: flare-up symptom is chosen from
swelling, pain, erythema, warmth, stiffness, decreased range of motion
This list effectively narrows what counts as the trigger for the flare-phase dose (at least in the dependent-claim sense).
Weight-band independent claim families and their dependents
-
Claim 13 dependents (10–20 kg)
- Claim 14: 5 mg administered for 56 days
- Claim 15: 5 mg for 56 days, plus +28 days if symptoms persist
- Claim 16: symptom list (same six items)
-
Claim 17 dependents (20–40 kg)
- Claim 18: 6 mg administered for 56 days
- Claim 19: 6 mg for 56 days, plus +28 days if symptoms persist
- Claim 20: symptom list
-
Claim 21 dependents (40–60 kg)
- Claim 22: 7.5 mg administered for 56 days
- Claim 23: 7.5 mg for 56 days, plus +28 days if symptoms persist
- Claim 24: symptom list
Claim Map: Dosing Schedules by Patient Profile
Below is a consolidated “schedule table” from the claim text you provided.
Dose and duration matrix
| Claim family |
Weight / maturity condition |
Non-flare daily dose |
Flare daily dose (duration) |
Post-flare daily dose (duration) |
Extension |
| Claim 1 |
none stated in independent; dependents include weight >60 kg and skeletal maturity ≥90% |
5 mg |
20 mg for 28 days |
10 mg for ≥56 days |
not stated in Claim 1; extension appears in Claim 3 |
| Claim 7 |
none stated in independent |
not specified |
20 mg for 28 days |
10 mg for ≥56 days |
not stated in Claim 7; extension appears in Claim 9 |
| Claim 13 |
10–20 kg |
2.5 mg |
10 mg for 28 days |
5 mg for ≥56 days |
Claim 15: +28 days if symptoms persist |
| Claim 17 |
20–40 kg |
3 mg |
12.5 mg for 28 days |
6 mg for ≥56 days |
Claim 19: +28 days if symptoms persist |
| Claim 21 |
40–60 kg |
4 mg |
15 mg for 28 days |
7.5 mg for ≥56 days |
Claim 23: +28 days if symptoms persist |
Discrete alternate formulations inside the claim set
- Claim 1 vs Claim 7: Claim 1 adds a non-flare maintenance dose (5 mg daily), while Claim 7 focuses on the flare and immediate post-flare window.
- Claim 13/17/21: Independent weight-banded regimens are structurally parallel but use smaller dose tiers.
Practical Scope: What Would Count as Practice of the Claimed Method?
On a strict reading, practicing the claimed method requires all elements of a given claim:
- Indication: subject has FOP
- Endpoint type: “reduce the volume of new heterotopic ossification”
- Oral dosing of palovarotene
- Flare-state detection: non-flare vs flare-up symptom period
- Exact mg and duration windows as recited
Near-term infringement risk drivers
- Running trials or real-world protocols that use exactly the same mg amounts and 28/≥56-day timing will align closely with these claims.
- If a protocol includes flare-triggered therapy with palovarotene 20 mg daily for 28 days, followed by 10 mg daily for at least 56 days, it will map directly to the Claim 1/7 dosing spine.
Design-around pressure points
The claims create multiple pressure points:
- break the 28-day flare dosing window (e.g., use a different duration or dose ramp),
- break the 10 mg post-flare dose in the general framework,
- adjust dosing by different weight cutoffs and/or different mg increments so that weight bands do not land on the claimed ranges and mg levels.
Patent Landscape Signals (Based on Claim Text Alone)
With only the claim text, the landscape conclusions must be anchored to what is structurally implied by claim construction.
Likely landscape structure: regimen-formulation claims layered on palovarotene for FOP
This patent is a method-of-treatment regimen. In a typical antitarget landscape for well-known molecules like palovarotene, competing filings often segment along:
- molecule and salt,
- dosing regimens and titration,
- treatment duration windows tied to flare events,
- risk mitigation windows.
This patent’s claim set indicates the filing intends to protect flare-driven scheduling and weight-based pediatric/adolescent dosing rather than protecting general use of palovarotene.
How this claim set might be positioned against other palovarotene FOP patents
Even without identifying other US patents by number, the claim content implies:
- other patents may protect different regimens (different dose levels, different flare-start rules, different durations),
- this one specifically locks onto the 20 mg/10 mg structure for the “flare/post-flare” pair and locks onto 2.5/10/5, 3/12.5/6, 4/15/7.5 for weight bands.
Therefore, a competitor would expect the freedom-to-operate pinch point to be the exact pairing of:
- flare dose for 28 days and
- post-flare dose for ≥56 days
for the same subject classification used in the claim.
What Is the Claim “Coverage Envelope”? (Infringement Envelope Summary)
If the subject fits the Claim 1 structure
Coverage is broad if a protocol matches:
- non-flare: 5 mg daily
- flare: 20 mg daily for 28 days
- post-flare: 10 mg daily for at least 56 days
If the subject fits the weight-banded independent claim structures
Coverage is specific if a protocol uses:
- 10–20 kg: 2.5 mg non-flare, 10 mg flare (28 days), 5 mg post-flare (≥56 days)
- 20–40 kg: 3 mg non-flare, 12.5 mg flare (28 days), 6 mg post-flare (≥56 days)
- 40–60 kg: 4 mg non-flare, 15 mg flare (28 days), 7.5 mg post-flare (≥56 days)
Extension logic
If the protocol adds:
- +28 days after the baseline ≥56-day window when symptoms persist,
it aligns with dependent extension claims.
Key Takeaways
- US 12,458,626 claims oral palovarotene dosing regimens to reduce new HO volume in FOP, with a core schedule built on 28-day flare dosing followed by ≥56-day post-flare dosing.
- The claim set is anchored by exact dose tiers:
- Non-flare 5 mg / Flare 20 mg (28 days) / Post-flare 10 mg (≥56 days) (Claim 1) and
- weight-banded regimens using 2.5/10/5, 3/12.5/6, 4/15/7.5 (Claims 13/17/21).
- Dependent claims narrow flare-trigger symptoms to swelling, pain, erythema, warmth, stiffness, decreased range of motion and include optional +28-day extension if symptoms persist.
- The practical risk area for FTO is the exact combination of palovarotene dose level + flare window (28 days) + post-flare duration (≥56 days), plus weight stratification when pediatric protocols mirror the claimed bands and mg increments.
FAQs
1) Does the patent claim palovarotene itself or only dosing methods?
It claims methods of treatment using oral palovarotene dosing regimens, not the molecule.
2) What is the single most important timing element in the claims?
The flare-up dosing duration is 28 days.
3) What post-flare duration does the patent require at minimum?
At least 56 days after the 28-day flare period.
4) Are flare-up symptoms defined generically or by a fixed list?
The dependent claims define them by a fixed list: swelling, pain, erythema, warmth, stiffness, decreased range of motion.
5) Are there pediatric weight bands in the independent claims?
Yes. Independent claims are tied to 10–20 kg, 20–40 kg, and 40–60 kg with different dose tiers.
References
[1] User-provided claim text for US Drug Patent 12,458,626 (claims 1-24).
